Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRN Amarin	$16.65 -1.0%	$12.18	$7.08 ▼ $17.18	$348.08M	0.82	82,151 shs	111,542 shs
INO Inovio Pharmaceuticals	$2.14 +4.9%	$2.01	$1.42 ▼ $12.33	$74.82M	1.31	647,392 shs	1.81 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRN Amarin	-0.95%	+2.84%	+41.82%	+96.99%	+18.09%
INO Inovio Pharmaceuticals	+4.90%	-3.17%	+1.90%	+34.59%	-74.61%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMRN Amarin	0.7503 of 5 stars	0.5	5.0	0.0	0.0	3.3	0.0	0.6
INO Inovio Pharmaceuticals	3.6675 of 5 stars	3.3	1.0	0.0	4.3	3.1	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMRN Amarin	1.00	Sell	$12.00	-27.93% Downside
INO Inovio Pharmaceuticals	2.50	Moderate Buy	$9.75	355.61% Upside

Current Analyst Ratings Breakdown

Latest AMRN and INO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	AMRN Amarin	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sell ➝ Sell	$7.00 ➝ $12.00
5/14/2025	INO Inovio Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform	$5.00 ➝ $5.00
5/14/2025	INO Inovio Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$15.00 ➝ $13.00
4/17/2025	AMRN Amarin	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sell ➝ Sell	$20.00 ➝ $7.00

(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMRN Amarin	$228.61M	1.51	N/A	N/A	$23.62 per share	0.70
INO Inovio Pharmaceuticals	$220K	356.70	N/A	N/A	$1.90 per share	1.13

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMRN Amarin	-$82.18M	-$3.64	N/A	N/A	N/A	-41.07%	-17.21%	-12.16%	7/30/2025 (Estimated)
INO Inovio Pharmaceuticals	-$107.25M	-$3.19	N/A	N/A	N/A	N/A	-136.93%	-89.99%	8/6/2025 (Estimated)

Latest AMRN and INO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/30/2025	Q2 2025	AMRN Amarin	-$0.60	N/A	N/A	N/A	$45.45 million	N/A
5/13/2025	Q1 2025	INO Inovio Pharmaceuticals	-$0.74	-$0.51	+$0.23	-$0.51	$0.01 million	$0.07 million
5/7/2025	Q1 2025	AMRN Amarin	-$0.06	-$0.04	+$0.02	-$0.04	$50.75 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMRN Amarin	N/A	N/A	N/A	N/A	N/A
INO Inovio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMRN Amarin	N/A	3.53	2.55
INO Inovio Pharmaceuticals	N/A	2.63	2.63

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMRN Amarin	22.25%
INO Inovio Pharmaceuticals	26.79%

Insider Ownership

Company	Insider Ownership
AMRN Amarin	3.30%
INO Inovio Pharmaceuticals	2.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMRN Amarin	360	20.71 million	20.02 million	Optionable
INO Inovio Pharmaceuticals	320	36.67 million	35.83 million	Optionable

AMRN and INO Headlines

Recent News About These Companies

Inovio Pharmaceuticals stock plunges after announcing public offering

July 2 at 8:36 PM | uk.investing.com

Inovio Pharma Shares Slide on Plans for Public Offering

July 2 at 8:36 PM | marketwatch.com

INOVIO Announces Proposed Public Offering

July 2 at 4:16 PM | prnewswire.com

Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development

July 1 at 7:00 AM | globenewswire.com

Inovio Pharmaceuticals (NASDAQ:INO) Upgraded by Wall Street Zen to Hold Rating

June 29, 2025 | americanbankingnews.com

Wall Street Zen Upgrades Inovio Pharmaceuticals (NASDAQ:INO) to Hold

June 27, 2025 | marketbeat.com

Recurrent Respiratory Papillomatosis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Precigen, Inovio Pharma

June 23, 2025 | theglobeandmail.com

Inovio Pharmaceuticals (NASDAQ:INO) Will Have To Spend Its Cash Wisely

June 19, 2025 | finance.yahoo.com

Inovio Pharmaceuticals (NASDAQ:INO) Rating Lowered to Sell at Wall Street Zen

June 14, 2025 | marketbeat.com

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Position Boosted by Bank of America Corp DE

June 7, 2025 | marketbeat.com

Inovio shareholders approve board nominees and proposals

May 24, 2025 | investing.com

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q1 2025 Earnings Call Transcript

May 14, 2025 | msn.com

INOVIO Pharmaceuticals, Inc.: INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 14, 2025 | finanznachrichten.de

Q1 2025 Inovio Pharmaceuticals Inc Earnings Call

May 14, 2025 | finance.yahoo.com

Inovio Pharmaceuticals, Inc. (INO) Q1 2025 Earnings Call Transcript

May 13, 2025 | seekingalpha.com

Inovio Pharmaceuticals (INO) Reports Q1 Loss, Tops Revenue Estimates

May 13, 2025 | zacks.com

INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 13, 2025 | prnewswire.com

Inovio Pharmaceuticals, Inc. (INO) Citizens JMP Life Sciences Conference (Transcript)

May 9, 2025 | seekingalpha.com

INOVIO to Present at Upcoming Scientific and Investor Conferences

April 30, 2025 | prnewswire.com

INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025

April 29, 2025 | prnewswire.com

Bet on These 5 Top-Ranked Stocks With Rising P/E

April 21, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMRN and INO Company Descriptions

Amarin NASDAQ:AMRN

$16.65 -0.16 (-0.95%)

Closing price 07/2/2025 04:00 PM Eastern

Extended Trading

$16.52 -0.13 (-0.75%)

As of 07/2/2025 07:08 PM Eastern

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Inovio Pharmaceuticals NASDAQ:INO

$2.14 +0.10 (+4.90%)

Closing price 07/2/2025 04:00 PM Eastern

Extended Trading

$1.66 -0.48 (-22.62%)

As of 07/2/2025 07:59 PM Eastern

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time